EGFR and non-small cell lung carcinoma: In a recent study investigating the impact of TMB on clinical outcomes of NSCLC patients treated with EGFR TKIs, TMB was found to be remarkably lower in EGFR-mutated tumors (n = 153) than EGFR wild-type tumors (n = 1,849) (median 3.77 versus 6.12 mutations/Mb; P < 0.0001) (60).